(HER2)-Negative Breast Cancer – Clinipace – OVELIA – Tolmar
People with (HER2)-Negative Breast Cancer are asked to participate in a research study being conducted by Montefiore Medical Center.
You may be eligible to participate in this study if you:
FEMALE:
- Are age 18 to 55
- Have a diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer
- Are premenopausal
MALE:
- Are age 18 or older
- Have a diagnosis of Stage I, II, or III HR+, HER2-negative breast cancer
You may NOT participate in this study if you:
FEMALE:
- Are breastfeeding
- Have unacceptable hepatic or renal function
- Have a history of treatment for osteopenia/osteoporosis
- Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mTOR inhibitors, or hormone replacement therapy within 3 months
MALE:
- Have unacceptable hepatic or renal function
- History of treatment for osteopenia/osteoporosis
- Prior use of tamoxifen, other SERMs (eg, raloxifene) or antagonists (eg, fulvestrant), aromatase inhibitor, mTOR inhibitors, or hormone replacement therapy within 3 months
Contact Information
Ambar Baez, Study Coordinator
1695 Eastchester Road Bronx, NY 10461
Phone: (718) 405-8578
Fax: (718) 405-8230
Email: ambaez@montefiore.org